Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRSH5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,969
Award facts
- Contract value 100% obligated
- $20,969.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $20,969.28 delivery order to DMS Pharmaceutical Group Inc. on May 12, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for Xolair 300 mg/2 ml autoinjector.
DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, Illinois. The order is priced firm fixed-price with an ultimate completion date of June 3, 2026.
Quick answers
Who was awarded contract SPE2DR26FRSH5?
SPE2DR26FRSH5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on May 12, 2026.
How much is contract SPE2DR26FRSH5 worth?
The government has obligated $20,969 on SPE2DR26FRSH5.
Is contract SPE2DR26FRSH5 an order under another contract?
Yes. SPE2DR26FRSH5 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRSH5 competed?
The extent of competition for SPE2DR26FRSH5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award